NCT00651144View on ClinicalTrials.gov

Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317)

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

May 31, 2003

Study Completion Date

May 31, 2003

Conditions
HypercholesterolemiaAtherosclerosis
Interventions
DRUG

Ezetimibe + Rosuvastatin

oral tablets; rosuvastatin 10 mg + ezetimibe 10 mg, once daily for 14 days

DRUG

Rosuvastatin

oral tablets; rosuvastatin 10 mg + ezetimibe placebo once daily for 14 days

DRUG

Placebo

oral tablets; two ezetimibe placebo once daily for 14 days

DRUG

Ezetimibe

oral tablets; ezetimibe 10 mg + ezetimibe placebo once daily for 14 days

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Organon and Co

INDUSTRY

NCT00651144 - Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317) | Biotech Hunter | Biotech Hunter